Skip to main content
Xiamen Amoytop Biotech Co., Ltd. logo

Xiamen Amoytop Biotech Co., Ltd. — Investor Relations & Filings

Ticker · 688278 ISIN · CNE100003RT3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 580 across all filing types
Latest filing 2026-05-26 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688278

About Xiamen Amoytop Biotech Co., Ltd.

https://www.amoytop.com/en/

Xiamen Amoytop Biotech Co., Ltd. is a biopharmaceutical enterprise specializing in the research, development, and commercialization of recombinant protein drugs. The company focuses on therapeutic areas including viral hepatitis and oncology. Its flagship product, Pegbin (pegylated interferon alfa-2b), is a long-acting interferon used primarily for the treatment of chronic hepatitis B, aiming for clinical cure. Other key products include Leucogen (molgramostim), Filgrastim, and Oprelvekin, which address chemotherapy-induced neutropenia and thrombocytopenia. Amoytop Biotech leverages its proprietary long-acting protein drug technology platform to develop innovative biologics. The company maintains a robust pipeline of candidates targeting immune-related diseases and metabolic disorders, emphasizing high-quality manufacturing standards and clinical efficacy.

Recent filings

Filing Released Lang Actions
特宝生物：关于向不特定对象发行可转换公司债券申请获得上海证券交易所上市审核委员会审核通过的公告
Capital/Financing Update Classification · 85% confidence The document is an announcement by Xiamen Tebao Bioengineering Co., Ltd. that the Shanghai Stock Exchange Listing Review Committee approved its application to issue convertible bonds to unspecified investors, with next steps pending CSRC registration. This is a financing activity (issuance of convertible debt) and thus fits the Capital/Financing Update category.
2026-05-26 Chinese
特宝生物：2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is an official announcement by Xiamen Tebo Bioengineering Co., Ltd. detailing the 2025 annual dividend distribution (“权益分派实施公告”), including per-share cash dividend, record/ex-dividend/payment dates, resolution approvals, distribution mechanics, and tax treatment. This exactly matches the “Notice of Dividend Amount” category – an announcement of dividend amounts and payment details to shareholders.
2026-05-22 Chinese
国金证券股份有限公司关于厦门特宝生物工程股份有限公司差异化权益分派事项的核查意见
Notice of Dividend Amount Classification · 78% confidence The document is a formal sponsor’s review opinion (“核查意见”) concerning the company’s differentiated rights distribution plan, which centers on a cash dividend of RMB 6.20 per 10 shares, total dividend amount, ex‐rights/ex‐dividend treatment and related dates. It provides detailed dividend distribution terms and calculation formulas. This fits the “Notice of Dividend Amount” category, which covers announcements of dividend amounts, payment dates and distribution details.
2026-05-22 Chinese
特宝生物：关于以集中竞价交易方式回购股份方案暨回购报告书
Transaction in Own Shares Classification · 93% confidence The document is a detailed announcement by Xiamen Tebao Biological Engineering Co., Ltd. regarding a share repurchase plan via centralized bidding. It includes the board resolution date, repurchase amount, price limit, purpose (employee share plan, convertible bonds), funding sources, implementation procedures, authorized maximum and minimum repurchase amount, risks, and related disclosures. This is a classic share buyback (transaction in own shares) announcement, matching category “Transaction in Own Shares” (POS).
2026-05-11 Chinese
特宝生物：关于股份回购进展及实施结果暨股份变动的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from a company about the progress and results of its share repurchase program, including details such as the number of shares repurchased, prices, funding sources, and future plans for the repurchased shares. It includes specific data on the repurchase execution and compliance with regulatory requirements. The document is not a financial report, earnings release, or management discussion, but rather a formal disclosure of share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back or selling its own shares.
2026-05-08 Chinese
特宝生物：2026年第三次临时股东会法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, and voting procedures of the 2026 third extraordinary general meeting (临时股东会) of Xiamen Tebao Bioengineering Co., Ltd. It details the legality and compliance of the meeting's call, the qualifications of attendees, and the voting results. The document is not a financial report, earnings release, or management discussion, but a legal opinion related to a shareholders' meeting. This type of document is best classified under Regulatory Filings (RNS) as it is a compliance/legal procedural filing that does not fit other specific categories such as AGM Information or Declaration of Voting Results, since it is a legal opinion rather than the meeting materials or voting results announcement itself. The document length is under 5,000 characters, and it is a standalone legal opinion letter, not a report publication announcement or certification. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2026-05-07 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.